| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1006506178 |
| P356 | DOI | 10.1186/S12967-016-0778-Z |
| P2888 | exact match | https://scigraph.springernature.com/pub.10.1186/s12967-016-0778-z |
| P932 | PMC publication ID | 4722680 |
| P698 | PubMed publication ID | 26801900 |
| P5875 | ResearchGate publication ID | 291420702 |
| P50 | author | Paolo Gasparini | Q95346511 |
| Giorgia Girotto | Q37634720 | ||
| Davide Bedognetti | Q39187019 | ||
| Massimiliano Cocca | Q42533507 | ||
| P2093 | author name string | Martina La Bianca | |
| P2860 | cites work | Pharmacogenetics, pharmacogenomics, and individualized medicine | Q23919667 |
| Pharmacogenetic assessment of clinical outcome in patients with metastatic breast cancer treated with docetaxel plus capecitabine. | Q53272686 | ||
| FcγR2A and 3A polymorphisms predict clinical outcome of trastuzumab in both neoadjuvant and metastatic settings in patients with HER2-positive breast cancer. | Q54630456 | ||
| Pharmacogenetics: From Bench to Byte | Q63865833 | ||
| Pharmacokinetics of 5-fluorouracil in mutant Nagase analbuminemic rats: faster metabolism of 5-fluorouracil via CYP1A | Q79581120 | ||
| Breast cancer heterogeneity may explain peaks in recurrence | Q80224502 | ||
| Novel SLC22A16 polymorphisms and influence on doxorubicin pharmacokinetics in Asian breast cancer patients | Q80456058 | ||
| Role of the HER2 [Ile655Val] genetic polymorphism in tumorogenesis and in the risk of trastuzumab-related cardiotoxicity | Q80785284 | ||
| Relationship between single nucleotide polymorphisms and haplotypes in DPYD and toxicity and efficacy of capecitabine in advanced colorectal cancer | Q83882655 | ||
| Pharmacogenetics of adjuvant breast cancer treatment with cyclophosphamide, epirubicin and 5-fluorouracil | Q87433062 | ||
| A map of human genome variation from population-scale sequencing | Q24617794 | ||
| PLINK: a tool set for whole-genome association and population-based linkage analyses | Q24677407 | ||
| Pharmacogenomics of breast cancer therapy: an update | Q27006783 | ||
| Strong association of a common dihydropyrimidine dehydrogenase gene polymorphism with fluoropyrimidine-related toxicity in cancer patients | Q28474358 | ||
| Pathogenic variants for Mendelian and complex traits in exomes of 6,517 European and African Americans: implications for the return of incidental results | Q30408185 | ||
| Influence of pharmacogenetics on response and toxicity in breast cancer patients treated with doxorubicin and cyclophosphamide. | Q33747406 | ||
| Genetic characterization of northeastern Italian population isolates in the context of broader European genetic diversity | Q34318389 | ||
| Clinical Pharmacogenetics Implementation Consortium guidelines for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing | Q34367423 | ||
| Genome-wide associations and functional genomic studies of musculoskeletal adverse events in women receiving aromatase inhibitors | Q34488758 | ||
| CYP2D6 genotype and tamoxifen response for breast cancer: a systematic review and meta-analysis | Q35009604 | ||
| Concurrent vs sequential adjuvant chemotherapy and hormone therapy in breast cancer: a multicenter randomized phase III trial. | Q35460114 | ||
| Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials | Q35740423 | ||
| A critical review of the role of Fc gamma receptor polymorphisms in the response to monoclonal antibodies in cancer | Q36547750 | ||
| Genetic associations with toxicity-related discontinuation of aromatase inhibitor therapy for breast cancer | Q36823146 | ||
| Molecular signatures mostly associated with NK cells are predictive of relapse free survival in breast cancer patients. | Q36960012 | ||
| Association of CYP3A4/5, ABCB1 and ABCC2 polymorphisms and clinical outcomes of Thai breast cancer patients treated with tamoxifen | Q37140638 | ||
| A mitochondrial target sequence polymorphism in manganese superoxide dismutase predicts inferior survival in breast cancer patients treated with cyclophosphamide | Q37229749 | ||
| Analysis of Fcγ receptor IIIa and IIa polymorphisms: lack of correlation with outcome in trastuzumab-treated breast cancer patients | Q37292031 | ||
| Omics-based clinical trial designs | Q38087892 | ||
| The economics of biobanking and pharmacogenetics databasing: the case of an adaptive platform on breast cancer | Q38091211 | ||
| Somatic mutation in cancer and normal cells | Q38592662 | ||
| Prognostic and predictive immune gene signatures in breast cancer. | Q38595111 | ||
| Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. | Q40001571 | ||
| Heterozygosity for a point mutation in an invariant splice donor site of dihydropyrimidine dehydrogenase and severe 5-fluorouracil related toxicity | Q42544952 | ||
| MnSOD rs4880 and XPD rs13181 polymorphisms predict the survival of breast cancer patients treated with adjuvant tamoxifen | Q42706074 | ||
| Detailed analysis of five mutations in dihydropyrimidine dehydrogenase detected in cancer patients with 5-fluorouracil-related side effects | Q44667162 | ||
| Different in vitro metabolism of paclitaxel and docetaxel in humans, rats, pigs, and minipigs | Q44904693 | ||
| Role of pharmacogenetics on adjuvant chemotherapy-induced neutropenia in Chinese breast cancer patients. | Q51297212 | ||
| Significant role of CYP450 genetic variants in cyclophosphamide based breast cancer treatment outcomes: a multi-analytical strategy. | Q51739454 | ||
| Association between the HER2 Ile655Val polymorphism and response to trastuzumab in women with operable primary breast cancer. | Q53241143 | ||
| P921 | main subject | Italy | Q38 |
| personalized medicine | Q2072214 | ||
| P304 | page(s) | 22 | |
| P577 | publication date | 2016-01-22 | |
| P1433 | published in | Journal of Translational Medicine | Q15716664 |
| P1476 | title | Pharmacogenetics driving personalized medicine: analysis of genetic polymorphisms related to breast cancer medications in Italian isolated populations | |
| P478 | volume | 14 |
Search more.